Heart failure (HF) is a complex clinical syndrome resulting from structural or functional impairments of ventricular filling or ejection of blood. HF has a poor prognosis and the burden to society remains tremendous. The unfulfilled expectation is that expanding our knowledge of the genetic architecture of HF will help to quickly advance the quality of risk assessment, diagnoses, and treatment. To date, genome-wide association studies (GWAS) of HF have led to disappointing results with only limited progress in our understanding and tempering the earlier expectations. However, the analyses of traits closely related to HF (also called 'endophenotypes') have led to promising and novel findings. For example, GWAS of NT-proBNP levels not only identified variants in the NNPA-NPPB locus but also substantiated data suggesting that natriuretic peptides in itself are associated with a lower risk of hypertension and HF. Many other genetic associates currently await experimental follow-up in which genes are prioritized based on bioinformatic analyses and various model organisms are employed to obtain functional insights. Promising genes with identified function could later be used in personalized medicine. Also, targeting specific pathogenic gene mutations is promising to protect future generations from HF, such as recently done in human embryos carrying the cardiomyopathy-associated MYBPC3 mutation. This review discusses the current status of GWAS of HF and its endophenotypes. In addition, future directions such as functional follow-up and application of GWAS results are discussed.
Introduction
Heart failure (HF) is a complex clinical syndrome resulting from structural or functional impairments of ventricular filling or ejection of blood. The complexity of HF lies at several levels. Structural or functional impairments can originate from a heterogeneous group of disorders, including those related to the pericardium, myocardium, endocardium, heart valves, blood vessels, or from metabolic abnormalities. 1 Furthermore, similar triggers and events (e.g. myocardial infarction, chemotherapy, genetic mutations, and pregnancy) might result in HF in some individuals but not in others, suggesting heterogeneity in susceptibility. The overall prevalence of HF is high with 6.5 million Americans aged 20 years or older diagnosed with HF, a number that is expected to increase with >45% in 2030. HF is also a common cause of death, one in eight deaths mentions HF on the death certificate. The burden for society is large; cost for treatment is estimated to be $30.7 billion dollar per annum. 2 Despite substantial progress in the diagnosis and treatment of HF, there continue to remain huge gaps in our knowledge on many aspects of HF development and progression. The rapid expansion of genetic analyses to study the genetic architecture of diseases has been considered a major opportunity to close knowledge gaps and to accelerate the development of novel strategies to prevent, diagnose, and treat HF.
In the past decades, we have learned a lot from disease causing genes by familial studies of monogenetic causes of HF. These familial HF syndromes have been increasingly well be pinned down to its disease causing variants. 3 More difficult is to identify the molecular causal pathways of heterogeneous polygenetic forms of HF. Genome-wide association studies (GWAS) provide a tool to progress our understanding of genes explaining increased susceptibility. In this review, we focus on heterogeneous forms of HF and summarize the recent advances of GWAS of HF and traits related to HF (endophenotypes). We will also speculate on future perspectives of the post-GWAS era, which should ultimately result in improved prevention and treatment of HF.
Understanding HF through GWAS
To date, five GWASes have been performed with HF as the primary trait and have led to identification of six loci and five candidate genes. In total, 10 468 HF cases and 33 029 controls have been studied 4 ( Table 1) . The first HF GWAS did not yield any genome-wide significant findings. The top locus identified was KIAA1598, which did not replicate in later efforts. 4 After this initial study, a meta-analysis of four population-based cohorts was performed for incident HF. In this study two loci (one near the USP3 gene and the other near the LRIG3 gene; Figure 1 ) were identified. 5 The USP3 gene produces an ubiquitin-specific protease and low concentrations or dysfunction of this protease was also possibly linked to onset and progression of hypertrophic cardiomyopathy (HCM) and HF. 6 LRIG3 is widely expressed and impacts tissue development and tumour progression. The LRIG3-knockout mice are more susceptible to develop spontaneous HF more often than wild-type mice. 7 However, the exact mechanism of how the LRIG3 gene is related to the development of HF remains to be elucidated. The following three GWASes investigated patients with idiopathic dilated cardiomyopathy (DCM), a form of HF that involves left ventricular (LV) dilatation and LV systolic dysfunction without an obvious aetiology. [8] [9] [10] These GWASs had overlapping study populations. The third and fourth GWAS both identified variants associated with the HSPB7 gene. 8, 9 The third GWAS identified the variant in the second intron of the HSPB7 gene. 8 The fourth GWAS located its variant on a region harbouring several genes, of which HSPB7 was considered the best candidate because it had been associated with advanced HF and systolic dysfunction. 9 HSPB7 encodes a heat shock protein almost exclusively expressed in cardiac and skeletal muscle that preserves contractile integrity by binding to and stabilizing sarcomeric proteins, decreasing susceptibility to adverse cardiac remodelling. 11 The fourth GWAS also identified a variant located in the BAG3 gene region. BAG3 is involved in autophagic protein degradation in aging cells and is expressed in striated muscle in the Z-disc. Autophagic degradation is essential for Z-disc integrity and muscle contractility. BAG3 mutations have been found to cause severe childhood muscular dystrophy with cardiomyopathy. 9 The fifth GWAS identified a locus with two variants. 10 These were closely located within the non-coding HLA complex group 22 (HCG22) gene in the major histocompatibility complex region 6p21. 3. 10 Possibly, these variants could increase the risk for DCM through genetically driven, inflammatory mechanisms, but this remains to be elucidated. The five candidate genes identified in 10 years by GWAS can be considered a small success. Difficulties of the HF phenotype are not only the limited power because it is a binary (and not a continuous) trait but also the considerable heterogeneity of HF. 12 Also by ignoring the severity of environmental contribution especially the 'trigger' (e.g. myocardial infarction, aortic stenosis, chemotherapy) can lead to misclassification of the HF 'susceptibility' (risk) phenotype. For example, a patient with HF resistant genetic variants might be misclassified as susceptible for HF after experiencing a very strong environmental 'trigger' (e.g. a very large myocardial infarction) while another patient with HF susceptible variants might not be classified as HF because the 'trigger' did not occurred at time of assessment. The significant contribution and variation of environmental factors resulting in HF, which could either protect individuals against or predispose individuals to HF should be included in modelling of genetic susceptibility. Therefore, two approaches to advance progress are being pursued. The first is by enlarging the sample size, for example in consortia such as Heart failure Molecular Epidemiology for Therapeutic targets (HERMES; http://www.hermesconsortium.org).
HERMES comprises 42 population-based studies and clinical trials across Europe and North America and includes over 30 000 HF cases and over 200 000 controls. Another approach is by using other, related, phenotypes such as blood biomarkers and LV structural and functional parameters to identify underlying pathways, genes and mechanisms. These can be referred to as 'endophenotypes' of HF.
Understanding HF through GWAS on endophenotypes
Endophenotypes can be defined as intermediate phenotypes (such as risk factors or biomarker levels) for a disorder or disease of interest that are specific and allow better identification of associated genetic variants.
The term originates from a 1966 paper on the geographical distribution of grasshoppers 13 and has been also widely adopted in psychiatry. 14 Identification of genetic variants associated with endophenotypes that play a significant role in the prevention, diagnosis, or management of HF might also provide insight in the underlying pathophysiology of HF ( Figure 2) . GWAS on several important HF risk factors, including lipids and diabetes mellitus, are discussed elsewhere in this issue. Table 2 provides an overview of studies and the number of loci found for each endophenotype discussed here. Figure 1 displays the intracellular role of candidate genes found for the endophenotypes.
Prevention related endophenotypes of HF

Coronary artery disease
Coronary artery disease (CAD) is the commonest cause of HF and has been studied in several GWAS. 15, 16 CAD and HF were shown to have a genetic correlation of 0.68, and increased genetic risk for CAD increased risk for HF and HF mortality. 15 CAD loci have been reviewed in detail recently 17 and are also discussed elsewhere in this issue. Candidate genes for CAD were not included in Figure 1 .
Diagnosis related endophenotypes of HF
Non-invasive imaging of cardiac structure and function
Several GWAS of LV structure and function traits have been performed ( Table 2) . [18] [19] [20] [21] [22] LV mass studies have identified one intragenic within KCNB1, whose protein product is dephosphorylated by calcineurin. 18 Calcineurin is associated with LV hypertrophy, possibly reflecting the mechanism for development of LV hypertrophy in hypertension, 18 ultimately increasing risk of HF. 23 Additionally, the candidate gene UBE2V2
was associated with LV mass. GWASes on LV diastolic internal dimension (LVDD) identified the 6q22 locus in which two candidate genes (SLC35F1 and C6orf204) that are expressed in cardiac tissue but their exact function is unclear. 19 Also, WIPI1, MTSS1, and ATXN2 were identified as candidate genes associated with LVDD. 20 
HSPB7 BAG3
Please see the description provided for Stark et al.
Study-specific ascertainment. There was no further ascertainment in the meta-analysis. Apparently sporadic idiopathic DCM diagnosed based on established criteria, 104 characterized by enlarged left ventricle diameter and low ejection fraction (< _45%) in the absence of causal factors, such a CAD. Only cases without affected relatives were included.
Member of a conserved family of cyto-protective co-chaperone proteins. Involved in autophagic protein degradation in aging cells and is expressed in striated muscle in the Z-disc.
Continued
Genome-wide studies in heart failure . ATXN2 was previously associated with blood pressure 24, 25 and CAD 26 providing a possibly explanation. Additionally, GWAS identified KLF5 as associated with ejection fraction and PPAPDC1A as associated with interventricular septal wall thickness. 21 One GWAS used highresolution 3D MRI, but did not report any identified loci. 22 One more study first performed a GWAS on cardiac hypertrophy and then examined the association between the identified single-nucleotide polymorphisms (SNPs) and HF or HF mortality. One variant located on 20p12 was associated with increased HF mortality risk. However, no clear candidate genes were identified in this region. 27 
Electrocardiographic traits
The electrocardiogram (ECG) provides information on the direction magnitude of the electrical field of the heart and several continues ECG traits have been linked to HF. A long PR interval, an increased QRS duration or a long QT interval has been linked to worse survival in patient with HF. 28, 29 Atrial fibrillation has been associated with HF, with rate vs. rhythm control studies indicating rate control may improve HF outcome. [30] [31] [32] [33] GWAS on ECG traits provided confirmation of earlier insights of genetics of HF and also identified new genes associated with HF Table 2 .
GWASes on PR interval has identified four locus: TBX5, SCN10A, CAV1, and ARHGAP24.
34 SCN10A has been associated with cardiac disorders such as long QT-syndrome, 35, 36 Brugada syndrome, sick sinus node syndrome, and atrial fibrillation. 32, 37 Also, GWASes identified two loci for HR (MYH6 and SLC35F1) and five for QRS duration (TBX5, SCN10A, 6p21, 10q21, and SLC35F1). 38, 39 The MYH6 gene mutations have been identified in HCM and DCM. 32 The C6orf204 gene was also associated with electrocardiographic traits, 32, 40 especially QT interval. 35, 41 GWAS meta-analysis on QRS duration in 14 studies including 40 407 individuals, identified 22 loci, mostly located in genes encoding cardiac sodium channels, calcium-handling proteins, transcription factors, or cyclin-dependent kinase inhibitors. 42 Another GWAS meta-analysis on the QRS complex identified 52 loci, associated with QRS duration, Sokolow-Lyon, Cornel land 12-lead sum product in 73 518 individuals. 38 In the 52 loci they identified 67 candidate genes, all involved in cardiovascular and muscular system development.
Blood biomarkers
3.2.3.1. Natriuretic peptides. Natriuretic peptides such as B type natriuretic peptide (BNP), its amino-terminal cleavage equivalent (NTproBNP), are strongly associated with cardiac dysfunction and key in diagnosis and prognosis of HF. 43, 44 Several GWAS of NT-proBNP levels 45, 46 have been performed, and found that minor alleles of variants in the NPPA and NPPB genes of the newly identified NPPA-NPPB locus were associated with higher plasma atrial natriuretic peptide, BNP and NTproBNP levels, and lower blood pressure and risk of hypertension, thereby potentially protecting against HF by tackling volume overload and high filling pressure. 25, 45 More recently, two novel loci (SLC39A8 and POC1B/GALNT4) were associated with NT-proBNP. 46 The minor allele of SLC39A8 was also associated with increased plasma NT-proBNP levels and decreased High Density Lipoprotein, 47 BMI, 48 schizophrenia, 49 and blood pressure. 50 GALNT4 may be involved in regulating NTproBNP production and variants in this locus were previously associated with risk of CV disease. 51 
Cardiac troponin T. Cardiac Troponin T (cTnT) is a filament
protein important in cardiac muscle contraction, and whose release in the blood indicates myocardial injury. A GWAS on cTnT in 11, 544 individuals of the general population without CAD and HF identified two loci, one in the TNNT2 gene, which encodes the cTnT protein, and the other near the NCOA2 gene, which promotes muscle cell maintenance and growth. The variant in TNNT2 was also associated with HF suggesting that common variation in cTnT might increase the susceptibility to develop HF. , and telomere length (TL) all give insights into pathophysiological features of HF as oxidative stress and inflammation, but also into to progression of HF. 43, [53] [54] [55] GWASes have been performed on sST2 levels, galectin-3, MR-pro-ADM, and TL. 54, [56] [57] [58] ILRL1 accounted for 36% of variation of sST2 levels. 56 ABO and LGALS3 together explained up to 30% of galectin-3 levels. 54 Both F12 and KLKB1 are associated with hypertension by activating the renin-angiotensin-aldosteron system (RAAS). 59 RAAS plays a critical role in the pathophysiology of HF, 60 with angiotensin-converting enzyme inhibitors being first-line pharmaceutical treatment in HF. 61 Seven loci associated with TL have been identified
and Mendelian randomization studies using these loci have suggested causal links between short genetically determined TL with cardiovascular disease 62 and HF risk factors such as CAD. 58 
Management related endophenotypes of HF
HF progression
In addition to HF development, also HF progression has been studied in several GWAS on HF mortality. One GWAS studied mortality in 2526 This locus is on 3p22 in the CMTM7 gene, which is expressed in leukocytes and the heart. Although the function of CMTM7 is unclear it has been suggested to be linked to angiogenesis. 63 Another GWAS of HF mortality in only European ancestry subjects with HF identified a variant in the 5q22 locus. 64 This SNP was located in an enhancer region and conferred increased activity of this enhancer in multiple human tissues.
Heart rate
Raised resting heart rate is a risk factor for events in HF 65 and is an important treatment target. 61 GWAS have identified many loci associated with resting heart rate, with recent studies bringing the total number of known loci up to 72, providing at least 102 candidate genes. 39, 66 Various loci are supported by evidence of gene-expression in human heart tissue and harbour known genes associated with cardiac biology and cardiac phenotypes such as cardiomyopathies, arrhythmias and congenital heart diseases that can all increase the risk of HF development although possibly the most interesting genes are those that have not a well-established function.
Mid-term implications
Although the results of GWAS represent an enormous opportunity to obtain novel biological insights possibly relevant to disease pathophysiology, most susceptibility loci await functional follow-up. Functional followup will be essential to understand GWAS findings and to leverage them for preventive, diagnostic and therapeutic advances. 67 The next sections will summarize steps that could be taken to gain more insights in the underlying mechanisms of HF related GWAS associations ( Figure 3 ). An example of functional follow-up is illustrated in (Figure 4) .
68,69
Data mining: gene prioritization
The main challenge for gaining biological insights from GWAS is identifying which genes and pathways explain the links with HF. Of all proteincoding genes (n = 20 314), 64% are expressed in the heart. 70 Most of these genes (n = 8760) characterize 'housekeeping genes', which are expressed in all tissues. When compared with the other tissues, 283 genes are specifically expressed in the heart and therefore can be hypothesized to be more relevant to the HF phenotype. 70 Also using knowledge on transcription factors, enhancers or co-expressions with other genes might help to link the most plausible gene in a particular locus. For example, the Data-driven Expression Prioritized Integration for Complex Traits (DEPICTs) tool employs an integrative analysis based on co-expression analyses to systematically prioritize candidate genes at associated loci. DEPICT highlights enriched pathways and identifies tissues/ cell types where genes from associated loci are highly expressed. 71 A recent hypothesis (coined 'omnigenetic model') of complex genetics developed by the group of Pritchard provides a novel challenges for data-mining effort. This hypothesis proposes that gene regulatory networks are interconnected to such an extent that all genes expressed in a particular cell/tissue will be affecting the function and expression of the core disease-related genes. If so, most GWAS will also identify variants in non-core genes and heritability might be explained for a large proportion by effects of non-core genes (not essentially related to the disease Figure 2 Endophenotypes of HF. The endophenotypes of HF studied by GWAS can be grouped in three categories. (1) endophenotypes related to the prevention of HF, e.g. CAD and cardiovascular risk factors discussed elsewhere in this issue; (2) endophenotypes related to the diagnosis of HF, for example non-invasive imaging of cardiac structure and function, electrocardiographic traits and blood biomarkers); and (3) endophenotypes associated with management of HF including heart rate and the progression of HF, e.g. HF mortality. 72 This might explain why many complex traits have association signals spread quite randomly across the genome and as we cannot (yet) differentiate by our analysis by core vs. non-core genes, GWAS is currently hindered in its ability to pinpoint important core HF genes.
Data mining: epigenetics
GWAS identify multiple genetic variants in non-coding regions possibly causing changes in gene expression levels rather changes in protein function. 73 Different epigenetic mechanisms control these differences in gene expression, which might be involved in the pathogenesis of HF. 69 Different epigenetic mechanisms have been proposed to play a role in the failing heart. 74 For example, histone methyltransferase is regulated by histone deacetylase inhibition and associated with pathological cardiac hypertrophy and fibrosis, whereas DNA methylation might directly induce cardiac cavity dilation and reduced pump function. 75 Epigenomewide association studies provide a systematic approach comparable to GWAS and have led to the identification of loci in which methylation differs in patients with DCM compared with controls. 76 To integrate epigenetic information with gene-expression data, several bioinformatic tools have been developed. A recent example of a bioinformatic approach to explore gene expression in relation to chromatin organizations across multiple human cell lines and primary tissues is the Hi-C Unifying Genomic Interrogator (HUGIn; http://yunliweb.its.unc. edu/HUGIn/). 77 The use of this tool can be exemplified by interrogating the rs10927875 variant, identified in one of the GWAS on HF ( Table 1) .
HUGIn identifies the interaction of rs10927875 and DDI2 in the left ventricle, rather than the reported candidate gene (HSPB7) proposed by the GWAS investigators ( Figure 5) . The variant is also significantly associated with the expression of DDI2 in left ventricle (P = 0.03) in the GTEx database providing a potential mechanism (https://www.gtexportal.org/ home/testyourown). Probabilistic Identification of Causal SNPs (PICS) is another tool that uses an algorithm based on mapping RNA and chromatin in primary immune cells to calculate the most likely causal SNPs given the observed association signal at a locus. 78 Based on PICS, rs10519210 is likely to be causal (100% certainty). Altogether, these tools provide alternative hypotheses of plausible genes in associated loci. A recent example of applying bioinformatic approaches and epigenetic experiments lead to the identification of EDN1 (Endothelin 1) instead of the PHACTR1 as causal gene to explain the association of rs9349379 with several cardiovascular diseases, including CAD and hypertension. 79 
Experimental validation
Pluripotent stem cells
Functional experiments in human cardiomyocytes might be of great interest to understand GWAS findings associated with HF phenotypes. Advancements in biotechnology have made it feasible to generate these human cardiomyocytes from embryonic stem cells, induced pluripotent stem cells (iPSCs) or somatic cells via direct cellular reprogramming. 80 iPCS platforms are being used for multiple purposes, including risk prediction, drug discovery and cardiotoxicity. 81 When exposed to environmental perturbation in vitro, hiPSC-derived cardiovascular cells might provide useful information on the patient's genomic disease susceptibility to environmental perturbations producing a disease phenotype comparable to the patient's in vivo condition. 81 Additionally, in HF it has been suggested that transplantation of iPSC-derived cardiomyocytes into the damaged heart (in vivo) leads to recovery of cardiac function, however many practicalities remain to be resolved before clinical application. 
Organoids
3D-engineered human cardiac organoids (hCOs) provide a potential functional model to study GWAS findings of heart phenotypes using experimental manipulations that are not feasible in vivo. 83 Various approaches have been exploited to fabricate hCOs and heart-on-a-chip devices that recapitulate the biology and physiology of a native heart. 84 For instance, microengineering strategies that rely on the use of topographic cues would induce alignment of the cardiomyocytes that assume a similar structure of the native myocardium 85 ; bioprinting strategies have enabled the incorporation of vasculature into the cardiac organoids while maintaining the anisotropy of the cardiomyocytes 86 ; and the adoption of flexible substrates seeded with cardiomyocytes could lead to spontaneously actuating heart wall-like patterns modelling a part of a beating heart. 87 
Mouse models
Humans and mice have a 78.5% amino acid sequence identity, 88 and multiple tools are available for manipulating the mouse genome and evaluating cardiac function 89 ( Figure 6 ). The International Mouse Phenotyping
Consortium created a genome-and phenome-wide catalogue of gene function by characterizing knockout-mouse strains across diverse biological systems through a broad set of standardized phenotyping test. 90 The analysis of 3328 genes currently (ongoing) are described, representing 15% of the mouse genome and identifying 360 new disease models. More than half of the genes analysed have never been investigated in a mouse before, and, for 1092 genes the molecular function or biological processes were previously unknown. 90 The Mouse Genome Database (http://www.informatics.jax.org/) provides information on availability and phenotype of mutant mouse strains and this resource can greatly accelerate functional follow-up of GWAS identified loci.
Figure 3
Different steps that could be taken after GWAS of (endophenotypes of) HF. The main challenge for obtaining biological insights from GWAS is identifying candidate causal genes and pathways that explain the SNP association with HF. Knowledge on transcription factors, enhancers, and co-expressions with other genes or epigenetics might help to link the most plausible gene in a particular locus. Cell models as pluripotent stem cells and hCOs provide a potential functional model to study GWAS findings of heart phenotypes using experimental manipulations that are not feasible in vivo. Human genes have many orthologs in animals like mice, fruit flies and zebrafishes. Multiple tools are available for manipulating the genomes of these animal models and therefore feasible for evaluating cardiac function. The ultimate application of novel HF knowledge initiated by GWAS findings lies in the improvement in prevention, diagnosis, therapy and interventions to improve human health. 
Fruit flies
In total 75% of the human disease genes have orthologues in fruit flies. 91 Fruit flies have the advantage of a compact genome that is easy to manipulate. 67, 92 Most lineages of the fly heart have been determined and many molecular markers are available for subsets of heart cells and lineages. Because the fly heart is not required for oxygen delivery to other tissues, which is provided by a tracheal system, the problem of early lethality in vertebrates is much less severe in flies. 93 A genome-wide library of the fruit fly RNAi transgenes enables the conditional inactivation of gene function in specific tissues, including the heart, of the intact organism. 94 A total of 22 270 transgenic lines have been generated, covering 88% of the predicted proteincoding genes in the fruit fly genome. 94 The effect of genetic manipulation on cardiac dimensions, heart rate, and cardiac death in response to stress can be easily evaluated in a time and money efficient manner.
Zebrafishes
Approximately 70% of human genes have at least one obvious zebrafish orthologue. 95 Zebrafish knockouts have been used to study the role of many genes in relation to HF and advances in mutagenesis technologies that rely on transcription activator-like effector nuclease and, more recently, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) nucleases targeted to specific genes 96, 97 has been instrumental in the widespread use of this model.
Application
The ultimate application of novel knowledge initiated by GWAS findings lies in the improvement in prevention, diagnosis, therapy and interventions to improve human health (Figure 3 ).
Risk assessment and modification of genetic risk through lifestyle behaviour
Accurate risk prediction might be relatively straightforward for monoand oligogenic conditions but is far more for difficult for complex diseases, including HF. 98 For complex diseases, genetic risk score strategies Figure 4 Post GWAS approaches of the meta-analysis on QRS duration and amplitude. Of the 52 loci, 974 annotated genes were located within 1 megabase of the sentinel genetic variants. Potential candidate genes were prioritized by four different methods. Genes were identified by determining the nearest gene or any other genes within 10 kb to the sentinel SNP; genes containing a nonsynonymous SNP affecting protein function in high LD (r 2 > 0.8) with the sentinel SNP; genes based on eQTL analyses and a literature-mining algorithm (GRAIL) identifying "cardiac," "muscle," and "heart" as the top three keywords describing the observed functional connections. In total, this strategy identified 67 candidate genes in 52 loci. Next, cardiac tissue-specific RNAi knockdown data in fruit flies was generated for the 67 candidate genes, pointing to a 2.3-fold enrichment of stress-induced cardiac death. Additionally, adult hearts of Cka/STRN, NACa/NACA, and EcR/NR1H RNAi showed severe cardiac defects and knockdown of Hand/HAND1 and Cka/STRN both had a reduced cardiac heart rate. Also, knockout mouse models were annotated for 45 have been applied by summing the number of the risk alleles. Genetic risk scores based on increasingly large GWAS discoveries are still very limited in their predictive power for future events. However, some data suggests that it can be useful to identify those in whom lifestyle interventions might be most beneficial. Although the relative risk reduction of lifestyle interventions might be the same across all quintiles of the genetic risk score, those with highest risk have the most absolute benefit. 99 Efforts to reduce risk of HF by lifestyle might be most cost-effective in the proportion with high genetic risk.
Personalized medicine and pharmacogenomics
Data related to HF pharmacogenomics are still limited. Examples of genes that have been investigated to this end are the ADRB1 gene, which is a likely candidate to predict response to b-blockers, and CYP2D6, which clearly affects the pharmacokinetics of metoprolol. However, the clinical impact of these association remains to be established. 100 A great amount of work lies ahead to identify the extent to which genetics influences the inter-individual variability in response to standard care HF drugs. For the development of new medication, GWAS results are also of interest. It has been shown that carriers of E40K and other inactivating mutations in ANGPTL4 (associated with lipid levels in several GWAS) had lower levels of triglycerides and a lower CAD risk compared with noncarriers. Also, inhibition of Angptl4 in mice and monkeys resulted in corresponding reductions in these values and might therefore be an interesting target for HF medication. 101 
Future generation
Recently, heterozygous MYBPC3 mutation in human preimplantation embryos was corrected using CRISPR/Cas9. 102 MYBPC3 dysfunctions have been proven to induce severe DCM, HCM, LV non-compaction and/or restrictive cardiomyopathies. 103 The efficiency, accuracy and safety of the approach presented suggest that it has potential to be used for the correction of heritable mutations in human embryos by complementing preimplantation genetic diagnosis. Theoretically, this strategy could be expanded to other mutations and common variants. However, ethical discussions are on-going and it remains unclear where to draw the line on risk and severity of phenotype to be corrected. 104 
Conclusions
GWAS of HF have yielded only limited success to date. Nevertheless, collaborations are set up to further increase the sample size and focus on Figure 5 Chromatin interaction and associated gene expression of variant rs10927875 identified by HUGIn and the GTEx database. Epigenetic analyses can be utilized to identify potential causal candidate genes, providing alternative ways to prioritize genes in HF associated loci. For rs10927875, a significant chromatin interaction was observed with the promoter of DDI2 in the left ventricle, rather than the reported candidate gene (HSPB7) proposed by the GWAS investigators. The variant is also significantly associated with the expression of DDI2 in left ventricle (P = 0.03) in the GTEx database providing a potential functional mechanism.
Genome-wide studies in heart failure . novel endophenotypes of HF instead of HF as a phenotype itself. The cause of association for the majority of implicated genetic loci is unknown and further functional follow-up remains to be performed. Future work will be essential for leveraging the true potential of GWAS findings for improving preventive, diagnostic, and therapeutic advances in HF. Figure 6 Manipulating the mouse genome. Human and mouse have a 78.5% amino acid sequence identity, multiple tools are available for manipulating the genome and evaluating cardiac function.
